Skip to content

Mounjaro vs Ozempic

By Dr Chad Okay4 min read

Both are weekly injections used for type 2 diabetes (and, in the UK, weight management). Mounjaro is tirzepatide (dual GLP-1 + GIP); Ozempic is semaglutide (GLP-1 only). Mounjaro produces stronger blood sugar control AND more weight loss in head-to-head trials. Ozempic has more cardiovascular outcomes evidence. For type 2 diabetes alone, both are excellent; Mounjaro slightly edges ahead on efficacy, Ozempic on track record.

If you're being prescribed either Mounjaro or Ozempic, the conversation has shifted in 2024-2025. Tirzepatide has matured into a real first-line contender. Here's how to think about the choice.

Head-to-head: SURPASS-2

The SURPASS-2 trial randomised 1,879 adults with type 2 diabetes inadequately controlled on metformin to either tirzepatide (5, 10, or 15 mg weekly) or semaglutide 1 mg weekly. After 40 weeks: HbA1c reduction of 2.0-2.3% on tirzepatide vs 1.9% on semaglutide. Weight loss: 7.6-11.2 kg on tirzepatide vs 5.7 kg on semaglutide. Tirzepatide won on both outcomes, with the largest gaps at the 10 mg and 15 mg doses.

What's different

DetailMounjaroOzempic
Active drugTirzepatideSemaglutide
Drug classDual GLP-1 + GIP agonistGLP-1 agonist
ManufacturerEli LillyNovo Nordisk
Maximum dose (diabetes)15 mg weekly2 mg weekly
HbA1c reduction~2.0-2.3% (5-15 mg, SURPASS-2)~1.9% at 1 mg (SURPASS-2); ~2.2% at the 2 mg maximum (SUSTAIN FORTE)
Weight loss in T2D at 40 weeks7-11 kg~6 kg
Cardiovascular outcomes dataSURPASS-CVOT (2025) non-inferior vs dulaglutideSUSTAIN-6 (positive)
UK NHS for diabetesIncreasingly usedLong-established

What's the same

  • Schedule: both weekly injections.
  • Pen design: very similar.
  • Storage: refrigerated, then room temperature in use.
  • Side effect categories: nausea, constipation, reflux, fatigue.
  • Rare serious risks: pancreatitis, gallstones, severe gastroparesis on both.
  • Mechanism overlap: GLP-1 receptor activation in both. Tirzepatide adds GIP.

Which to choose for type 2 diabetes

  • Need maximum HbA1c reduction: lean Mounjaro on the SURPASS-2 evidence.
  • Have established cardiovascular disease: Ozempic still has the strongest CV outcomes data (SUSTAIN-6). Tirzepatide CV trials are maturing.
  • Already responding well to Ozempic: probably no reason to switch.
  • Insufficient response on Ozempic 1 mg: ask about escalating to 2 mg first; consider Mounjaro if 2 mg also insufficient.
  • Newly diagnosed: both reach therapeutic effect over a similar timescale, and the local pathway, supply and cost usually decide.

Which to choose for weight loss

  • In the UK, the licensed weight-loss versions are Mounjaro (under that brand for both diabetes and weight) or Wegovy (semaglutide branded for weight loss).
  • Ozempic is NOT licensed for weight loss in the UK. If your reason is weight only, you'd be looking at Mounjaro vs Wegovy, not vs Ozempic.
  • Mounjaro for weight loss on the NHS: recommended by NICE (TA1026) for adults with BMI ≥35 plus at least one weight-related condition, with lower thresholds (usually reduced by 2.5) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
  • On weight loss specifically: Mounjaro 15 mg → ~21% loss at 72 weeks (SURMOUNT-1); Wegovy 2.4 mg → ~15% at 68 weeks (STEP 1).

Side effects compared

  • Nausea: similar on both at equivalent therapeutic doses (in the SURPASS-2 head-to-head, ~17-22% on tirzepatide vs ~18% on semaglutide; higher in obesity trials, peaking around 30% at dose escalations).
  • Constipation: Ozempic 1 mg ~6% (SUSTAIN/PIONEER); Mounjaro 5-15 mg ~6-9% (pooled SURPASS 1-5).
  • Diarrhoea: Mounjaro slightly higher across all doses.
  • Reflux: similar incidence on both.
  • Hypoglycaemia: low risk on either as monotherapy. Higher when combined with sulfonylureas or insulin.
  • Hair shedding: reported on both. It is thought to track rapid weight loss itself rather than the drug, and usually settles as weight stabilises.

If something feels wrong

This article is about comfort and everyday patterns, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

Cost and access

  • NHS for diabetes: both are routinely available; specific local pathways depend on the diabetes service.
  • NHS for weight loss: Mounjaro can be initiated in primary care or specialist weight management services under NICE TA1026, with phased rollout. Capacity is limited.
  • Private prescription: both £150-300/month depending on dose. Mounjaro often slightly cheaper at lower-equivalent doses.
  • Supply: intermittent for both since 2023; Mounjaro has been more stable in late 2025.

Common questions

On HbA1c reduction and weight loss, yes, SURPASS-2 showed clear advantages. On established cardiovascular outcomes data, Ozempic still leads. For most people newly starting GLP-1 therapy without prior CV disease, Mounjaro is the more efficacious choice.

The wearable built to help you see your own patterns.

Designed to help you explore your everyday signals without keeping a diary. Bowel sounds, eating windows, sleep recovery.

Sources

  1. 1SURPASS-2: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021)New England Journal of Medicine (PubMed)
  2. 2SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (2022)New England Journal of Medicine (PubMed)
  3. 3STEP 1: Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity (2021)New England Journal of Medicine (PMC)
  4. 4SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne et al, 2025 (-20.2% vs -13.7%)NEJM (PubMed)
  5. 5SUSTAIN-6: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016)New England Journal of Medicine (PubMed)
  6. 6SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, Nicholls et al, 2025 (non-inferior; 12.2% vs 13.1% primary outcome over median 4 years)NEJM (PubMed)
  7. 7SUSTAIN FORTE: semaglutide 2.0 mg vs 1.0 mg in type 2 diabetes, Frias et al, 2021 (HbA1c -2.2% vs -1.9% at week 40)The Lancet Diabetes & Endocrinology (PubMed)
  8. 8Mounjaro (tirzepatide) prescribing information: oral hormonal contraceptives and delayed gastric emptyingEli Lilly
  9. 9Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
  10. 10NICE TA1026: Tirzepatide for managing overweight and obesity - Recommendations (2024)NICE
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Read next

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.